Preble Janine M, Silpa-archa Sukhum, Foster C Stephen
aMassachusetts Eye Research and Surgery Institution (MERSI) bOcular Immunology and Uveitis Foundation (OIUF), Waltham, Massachusetts, USA cFaculty of Medicine, Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand dHarvard Medical School, Boston, Massachusetts, USA.
Curr Opin Ophthalmol. 2015 Nov;26(6):540-5. doi: 10.1097/ICU.0000000000000209.
Many patients suffer from the ocular manifestations associated with systemic lupus erythematosus (SLE). Retinal vasculitis and optic neuritis are two of the most vision-threatening complications that can be associated with the disease. Ocular manifestations are often associated with wide-spread systemic inflammation which can be fatal. Thus, immediate recognition and treatment is vital for a positive outcome.
There is an array of medications available to ophthalmologists for treating the ocular manifestations of SLE. Treating the underlying systemic disease is crucial, as well as treating the active ocular complications. Recently, more attention has been placed on evaluating biologic agents' efficacy in treating the systemic condition. New therapies continue to emerge that have the potential to provide benefit to patients suffering from SLE.
SLE is a serious systemic condition that may first present with ocular manifestations. Thus, it is crucial for ophthalmologists to be equipped with the knowledge to detect and adequately treat the disorder to avoid vision/life-threatening complications. More research is needed to determine which therapy provides the best outcome for patients with limited side-effects.
许多患者患有与系统性红斑狼疮(SLE)相关的眼部表现。视网膜血管炎和视神经炎是与该疾病相关的两种最具视力威胁的并发症。眼部表现通常与广泛的全身炎症相关,这可能是致命的。因此,立即识别和治疗对于取得良好结果至关重要。
眼科医生有一系列药物可用于治疗SLE的眼部表现。治疗潜在的全身性疾病至关重要,同时治疗活动性眼部并发症也很关键。最近,更多的注意力放在了评估生物制剂治疗全身性疾病的疗效上。新的治疗方法不断涌现,有可能为SLE患者带来益处。
SLE是一种严重的全身性疾病,可能首先表现为眼部症状。因此,眼科医生掌握检测和充分治疗该疾病的知识以避免视力/生命威胁性并发症至关重要。需要更多研究来确定哪种治疗方法能为患者提供最佳结果且副作用有限。